Epigenetic resensitization to platinum in ovarian cancer.

Preclinical studies have shown that hypomethylating agents reverse platinum resistance in ovarian cancer. In this phase II clinical trial, based upon the results of our phase I dose defining study, we tested the clinical and biologic activity of low-dose decitabine administered before carboplatin in platinum-resistant ovarian cancer patients. Among 17 patients with heavily pretreated and platinum-resistant ovarian cancer, the regimen induced a 35% objective response rate (RR) and progression-free survival (PFS) of 10.2 months, with nine patients (53%) free of progression at 6 months. Global and gene-specific DNA demethylation was achieved in peripheral blood mononuclear cells and tumors. The number of demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus less than 6 months (311 vs. 244 genes). Pathways enriched at baseline in tumors from patients with PFS more than 6 months included cytokine-cytokine receptor interactions, drug transporters, and mitogen-activated protein kinase, toll-like receptor and Jak-STAT signaling pathways, whereas those enriched in demethylated genes after decitabine treatment included pathways involved in cancer, Wnt signaling, and apoptosis (P < 0.01). Demethylation of MLH1, RASSF1A, HOXA10, and HOXA11 in tumors positively correlated with PFS (P < 0.05). Together, the results of this study suggest that low-dose decitabine altered DNA methylation of genes and cancer pathways, restoring sensitivity to carboplatin in patients with heavily pretreated ovarian cancer and resulting in a high RR and prolonged PFS.

[1]  Jingde Zhu,et al.  Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell , 2011, PloS one.

[2]  M. Seckl,et al.  A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells , 2011, PloS one.

[3]  S. Ambudkar,et al.  Improving cancer chemotherapy with modulators of ABC drug transporters. , 2011, Current drug targets.

[4]  R. Bast,et al.  Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.

[5]  D. Matei,et al.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.

[6]  I. Cree,et al.  Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy , 2010, British Journal of Cancer.

[7]  H. Hollema,et al.  The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. , 2010, Gynecologic oncology.

[8]  D. Matei,et al.  Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. , 2010, Gynecologic oncology.

[9]  A. Teschendorff,et al.  An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer , 2009, PloS one.

[10]  E. O’Neill,et al.  ATM Regulates a RASSF1A-Dependent DNA Damage Response , 2009, Current Biology.

[11]  Y. Assaraf,et al.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. , 2009, Neoplasia.

[12]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[13]  G. Barton,et al.  A cell biological view of Toll-like receptor function: regulation through compartmentalization , 2009, Nature Reviews Immunology.

[14]  I. Wistuba,et al.  Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.

[15]  M. Gore,et al.  Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Taylor,et al.  Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming. , 2009, Endocrinology.

[17]  Wei Hu,et al.  Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. , 2009, American journal of obstetrics and gynecology.

[18]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[19]  R. Medzhitov,et al.  Toll-like receptors and cancer , 2009, Nature Reviews Cancer.

[20]  K. Nephew,et al.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. , 2009, BMC medical genomics.

[21]  Martin Widschwendter,et al.  HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer , 2008, International journal of cancer.

[22]  K. Odunsi,et al.  Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer , 2008, Clinical Cancer Research.

[23]  Susan J Clark,et al.  DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. , 2008, Gynecologic oncology.

[24]  C. D. Salcido,et al.  Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes , 2008, British Journal of Cancer.

[25]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[26]  R. Coleman.  Preserving skeletal wellness throughout the continuum of care in patients with cancer. Introduction. , 2007, Seminars in oncology.

[27]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[29]  Ivo G Gut,et al.  DNA methylation analysis by pyrosequencing , 2007, Nature Protocols.

[30]  A. Gadducci,et al.  Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[31]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[32]  R. Ozols,et al.  The management of recurrent ovarian cancer. , 2007, Seminars in oncology.

[33]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[34]  K. C. Chan,et al.  Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers , 2007, British Journal of Cancer.

[35]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[36]  Pearlly Yan,et al.  Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer , 2005, Molecular Cancer Therapeutics.

[37]  Nikhil V. Shirahatti,et al.  Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. , 2005, Current Cancer Drug Targets.

[38]  David A Jones,et al.  Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Burger,et al.  Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. , 2005, Cancer research.

[40]  A. Kudelka,et al.  Retrospective review: re‐treatment of patients with ovarian cancer with carboplatin after platinum resistance , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[41]  M. Duffy,et al.  CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use , 2004, International Journal of Gynecologic Cancer.

[42]  U. Matulonis,et al.  Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. , 2004, Gynecologic oncology.

[43]  Paul Cairns,et al.  Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients , 2004, Cancer Research.

[44]  G. Schwartsmann,et al.  A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.

[45]  M. Teitell,et al.  DNA methylation in the immune system. , 2003, Clinical immunology.

[46]  M. Parmar,et al.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence , 2002, British Journal of Cancer.

[47]  P. Pohlmann,et al.  Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix , 2002, American journal of clinical oncology.

[48]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[50]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[51]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.